Nivå 1 · SyntesSystematisk översikt

Effects of omega-3 fatty acids on chronic pain: a systematic review and meta-analysis

Xie L, Wang X, Chu J, He X, Bao J, Xi Y, Wei X, Zhou Q

Frontiers in medicine · 5 november 2025

FÖRFATTARNAS SAMMANFATTNING

Background : Chronic pain afflicts approximately 20% of the global adult population and is frequently undertreated, with available pharmacologic options often associated with significant long-term adverse effects. Although omega-3 fatty acids are known for their anti-inflammatory and immunomodulatory effects, current clinical evidence regarding their efficacy in pain management remains inconclusive.

Objective : To determine how well omega-3 fatty acids reduce chronic pain, and to investigate how factors like disease type, dosage, treatment duration, and study design influence their effectiveness.

Methods : We searched four databases (PubMed, Embase, Cochrane Library, and Web of Science) from inception to 14 February 2025 with no language restrictions. Forty-one randomised controlled trials (RCTs; n = 3,759) met predefined criteria. Risk of bias was assessed with RoB 2. Pooled standardised mean differences (SMDs) for pain intensity were obtained through random-effects meta-analyses. Subgroup, sensitivity, and publication-bias analyses were also conducted.

Results : Omega-3 fatty acids showed a moderate, statistically and clinically significant reduction in pain intensity with a standardized mean difference (SMD) of -0.55 (95% CI -0.76 to -0.34; I 2 = 87%). The relief was noticeable at 1 month (SMD = -0.27) and improved by 6 months (SMD = -0.83). Lower doses (≤1.35 g/day) were more effective (SMD = -0.60) compared to higher doses (>1.35 g; SMD = -0.53). The benefits were significant for rheumatoid arthritis, migraine, and other mixed chronic pain conditions, but not for osteoarthritis or mastalgia. There was minimal publication bias according to trim-and-fill adjustment, and leave-one-out tests confirmed robust results.

Conclusion : Omega-3 fatty acid supplementation offers a clinically meaningful and time-dependent reduction in chronic pain, particularly at moderate doses and in certain disease contexts. Standardization of outcome measures, dose optimization, and long-term trials are needed to better define its role in pain management.

Systematic review registration : https://www.crd.york.ac.uk/PROSPERO/view/CRD420251035960, Identifier CRD420251035960.

Ursprunglig sammanfattning, återgiven utan ändringar. © Författarna, spridd under en Creative Commons CC BY-licens. De exakta villkoren anges i originalartikeln.

Vetenskaplig information; den ersätter inte råd från hälso- och sjukvårdspersonal. Att en studie finns i biblioteket utgör inget påstående om våra produkter.

← Alla studier